Protalix BioTherapeutics, Inc. (PLX)

1.1900 +0.0500 (+4.39%) 市場開市。 截至 01:54PM EDT。

Protalix BioTherapeutics, Inc.

Science Park
2 Snunit St. POB 455
Karmiel 2161401
Israel
972 4 902 8100
https://www.protalix.com

版塊: Healthcare
行業: Biotechnology
全職員工: 208

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Dror Bashan	President, CEO & Director	1.38M	無	1967
Mr. Eyal Rubin M.B.A.	Senior VP, CFO, Treasurer & Corporate Secretary	686.78k	無	1976
Mr. Yaron Naos	Senior Vice President of Operations	513.82k	無	1964
Ms. Yael Fellous	Vice President of Human Resources	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

公司管治

截至 2024年5月1日 止，Protalix BioTherapeutics, Inc. 的 ISS 管治質素評分為 5。 Pillar 分數正在審核中：4；董事會：8；股東權利：1；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。